The debut financing, backed by RA Capital, Leaps by Bayer and PureTech Health, will fund a head-to-head Phase 3 study in idiopathic pulmonary fibrosis
Newsflash:
Efanesoctocog alfa’s extended half-life offers Australian patients a substantially reduced infusion burden compared with existing factor VIII …
The debut financing, backed by RA Capital, Leaps by Bayer and PureTech Health, will fund a head-to-head Phase 3 study in idiopathic pulmonary fibrosis
Efanesoctocog alfa’s extended half-life offers Australian patients a substantially reduced infusion burden compared with existing factor VIII …
The debut financing, backed by RA Capital, Leaps by Bayer and PureTech Health, will fund a head-to-head Phase 3 study in idiopathic pulmonary fibrosis
Efanesoctocog alfa’s extended half-life offers Australian patients a substantially reduced infusion burden compared with existing factor VIII …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions in motor disability in Parkinson’s patients, with Phase 3 enrolment underway
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions in motor disability in Parkinson’s patients, with Phase 3 enrolment underway
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as the country’s …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Listen Now
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build a CNS platform that extends well beyond its blockbuster GLP-1 franchise
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, highlighting the regulatory tightrope in advanced therapeutics.
Early-stage data reveal tumour targeting and tolerability with radiolabelled GRPR antagonist therapy in metastatic prostate cancer
Long-term clinical data from Roche strengthen the case for disease-modifying therapies in spinal muscular atrophy and Duchenne muscular dystrophy.
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?